Director — Elena Ridloff: The filing discloses the appointment of a new director to fill a board seat, which is a standard governance event and not an executive departure.

of this Current Report on Form 8-K, including the Earnings Release, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). In addition, this information shall not be deemed incorporated by reference into any of the Company’s filings with the Securities and Exchange Commis…

of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for the purposes of Section 18 of the Securities Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth therein. Cautionary Note Regarding Forward-Looking Statements Certain statemen…

Director — Tamar Howson: Ms. Howson resigned as a member of the Board and Compensation Committee due to retirement, with Erik Lundgren appointed as a new director.

The filing is about an equity plan amendment, not a management change.

of this Current Report on Form 8-K and Exhibit 99.1 and Exhibit 99.2 attached hereto shall not be deemed “filed” for the purposes of Section 18 of the Securities Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth therein. Cautionary Note Regarding Forward-Looking Statements…

Chief Executive Officer — Erik Lundgren: Appointment of Erik Lundgren as Chief Executive Officer.

Chair of the Board — Michael W. Bonney: Appointment of Michael W. Bonney as Chair of the Board.

of this Current Report on Form 8-K, including the Press Release, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, this information shall not be deemed incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission, except as shall be expressly set forth by…

Chief Medical Officer — Michael A. Panzara, M.D., M.P.H.: Dr. Michael A. Panzara was hired as the new Chief Medical Officer.

Material Modification to Rights of Security Holders. The disclosure set forth in

Other Events. In connection with the result of the Special Meeting, the Board approved a reverse stock split of the Company’s issued and outstanding Common Stock, at a ratio of 1-for-10 shares, expected to effective at 12:01 a.m. Eastern Time on April 27, 2026 (the “Reverse Stock Split” and the shares of Common Stock following the Reverse Stock Split, the “New Common Stock”). The Company expects that the New Common Stock will begin trading on the Nasdaq Capital Market on the post-split basis…

Chief Executive Officer — Daniel Vitt: The company is commencing a search for a new CEO and Mr. Vitt's role will transition to a 'C-Suite' position focused on scientific strategy after the new CEO is hired.

Director and Chair of the Compensation Committee — Jon Congleton: Mr. Jon Congleton was appointed as a new director and will also act as Chair of the Compensation Committee.

Results of Operations and Financial Condition On February 26, 2026, Immunic, Inc. (the “Company”) issued a press release, a copy of which is furnished herewith as Exhibit 99.1, announcing the Company’s financial results for the quarter and year ended December 31, 2025 and providing a corporate update (the “Press Release”). The information contained in

Other Events. On February 13, 2026, the Company issued a press release announcing, among other things, the commencement of the Offering, a copy of which is attached hereto as Exhibit 99.1 and incorporated by reference herein. Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the Company’s intended use of the net proceeds fro…

Director — Maria Törnsén: Resigned as a member of the Board in connection with the Offering.

The Warrants are being sold and, upon exercise the securities underlying the Warrants, will be issued without registration under the Securities Act, in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as a transaction not involving a public offering and Rule 506 promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws.

Entry into a Material Definitive Agreement . Private Placement Securities Purchase Agreement On February 12, 2026, Immunic Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain accredited investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell, in a private placement (the “ Offering ”), pre-funded warrants (the “ Pre-Funded Warrants ”, and the shares of Common Stock (as defined below) issuable upo…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 5, 2026, Immunic, Inc. (the “Company”) received approval (the “Approval”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company’s application to transfer the listing of its common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market has been approved. The common stock will be transferred to the Nasdaq Capital…

Chief Executive Officer and President of Gliomic — Dr. Duane Nash: Dr. Duane Nash is being promoted to Chief Executive Officer and President of Gliomic, a subsidiary of the Company.

of this Current Report on Form 8-K, including the Press Release, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, this information shall not be deemed incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission (the “SEC”), except as shall be expressly…

of this Current Report on Form 8-K and Exhibit 99.1 and Exhibit 99.2 attached hereto shall not be deemed “filed” for the purposes of Section 18 of the Securities Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth therein. Cautionary Note Regarding Forward-Looking Statements…

Other Events On August 7, 2025, the Company posted an updated presentation (the “Presentation”) on its website. A copy of the Presentation is filed herewith as Exhibit 99.2 and is incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements Certain statements in this Current Report on Form 8-K, the Press Release and the Presentation are “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Privat…

of this Current Report on Form 8-K, including the Press Release, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, this information shall not be deemed incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission (the “SEC”), except as shall be expressly…